IMPORTANT ALERT Halper Sadeh LLC Investigates KLR, WMC, SGTX
| SGTXDelisted Stock | USD 21.11 0.33 1.54% |
Slightly above 61% of Sigilon Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Sigilon Therapeutics suggests that many traders are alarmed regarding Sigilon Therapeutics' prospects. Sigilon Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Sigilon Therapeutics' earnings reports, geopolitical events, and overall market trends.
Sigilon |
NEW YORK, July 03, 2023 Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws andor breaches of fiduciary
Read at benzinga.com
 |
Sigilon Therapeutics Fundamental Analysis
We analyze Sigilon Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sigilon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sigilon Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Sigilon Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Sigilon Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sigilon Therapeutics stock to make a market-neutral strategy. Peer analysis of Sigilon Therapeutics could also be used in its relative valuation, which is a method of valuing Sigilon Therapeutics by comparing valuation metrics with similar companies.
Peers
Sigilon Therapeutics Related Equities
| CDIO | Cardio Diagnostics | 14.81 | ||||
| UNCY | Unicycive Therapeutics | 7.27 | ||||
| XFOR | X4 Pharmaceuticals | 2.94 | ||||
| PHIO | Phio Pharmaceuticals | 2.45 | ||||
| INM | InMed Pharmaceuticals | 0.67 | ||||
| SONN | Sonnet Biotherapeutics | 0.72 | ||||
| NBY | NovaBay Pharmaceuticals | 1.61 | ||||
| RVPH | Reviva Pharmaceuticals | 2.61 | ||||
| ZVSA | ZyVersa Therapeutics | 3.60 | ||||
| GOVX | GeoVax Labs | 10.30 | ||||
| APLM | Apollomics | 15.62 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Sigilon Stock
If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |